Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
19
09
2022
accepted:
09
01
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Triplet regimens containing immunomodulatory drugs and proteasome inhibitors (PIs) have improved outcomes and extended survival for patients with relapsed/refractory multiple myeloma (RRMM). We evaluated updated health-related quality of life (HRQoL) findings from the phase 2 ELOQUENT-3 clinical trial (NCT02654132) after 4 years of treatment with elotuzumab plus pomalidomide and dexamethasone (EPd) and assessed the impact of the addition of elotuzumab on patients' HRQoL. HRQoL was assessed as an exploratory endpoint using the MD Anderson Symptom Inventory for Multiple Myeloma (MDASI-MM), which evaluates symptom severity, symptom interference, and HRQoL, and the 3-level EQ-5D, a patient-reported measure of health utility and general health. Statistical analyses included descriptive responder, longitudinal mixed-model, and time-to-first-deterioration (TTD) analyses using prespecified minimally important differences and responder definitions. Of 117 randomized patients, 106 (EPd, n = 55; pomalidomide and dexamethasone [Pd], n = 51) were eligible for inclusion in HRQoL analyses. Completion rates at almost all on-treatment visits were ≥80%. The proportion of patients treated with EPd who improved or maintained stable HRQoL until cycle 13 ranged from 82% to 96% for MDASI-MM total symptom score and 64% to 85% for MDASI-MM symptom interference. Across measurements, there were no clinically meaningful differences in changes from baseline between treatment arms, and TTD was not significantly different for EPd versus Pd. In conclusion, HRQoL was not impacted by the addition of elotuzumab to Pd and did not significantly deteriorate in patients with RRMM previously treated with lenalidomide and a PI in ELOQUENT-3.
Identifiants
pubmed: 36860268
doi: 10.1097/HS9.0000000000000843
pmc: PMC9970270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e843Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
J Clin Epidemiol. 1999 Sep;52(9):861-73
pubmed: 10529027
Support Care Cancer. 2014 Feb;22(2):417-26
pubmed: 24122403
Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e160-e175
pubmed: 33218965
Am J Hematol. 2020 Jun;95(6):672-690
pubmed: 32086970
Drugs. 2018 Jan;78(1):19-37
pubmed: 29188449
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Med Sci (Basel). 2021 Jan 20;9(1):
pubmed: 33498356
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
J Hematol Oncol. 2013 Feb 05;6:13
pubmed: 23384030
Hemasphere. 2023 Feb 24;7(3):e843
pubmed: 36860268
J Clin Oncol. 2023 Jan 20;41(3):568-578
pubmed: 35960908
Mayo Clin Proc. 2016 Jan;91(1):101-19
pubmed: 26763514
N Engl J Med. 2018 Nov 8;379(19):1811-1822
pubmed: 30403938
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669